Advertisement

 

 

Association of Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Use and Rates of Acute Myocardial Infarction, Stroke, and Overall Mortality in Patients with Type 2 Diabetes Mellitus in a Large Integrated Health System.

Association of Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Use and Rates of Acute Myocardial Infarction, Stroke, and Overall Mortality in Patients with Type 2 Diabetes Mellitus in a Large Integrated Health System.
Author Information (click to view)

Zimmerman RS, Hobbs TM, Wells BJ, Kong SX, Kattan MW, Bouchard J, Chagin KM, Yu C, Sakurada B, Milinovich A, Weng W, Bauman JM, Pantalone KM,


Zimmerman RS, Hobbs TM, Wells BJ, Kong SX, Kattan MW, Bouchard J, Chagin KM, Yu C, Sakurada B, Milinovich A, Weng W, Bauman JM, Pantalone KM, (click to view)

Zimmerman RS, Hobbs TM, Wells BJ, Kong SX, Kattan MW, Bouchard J, Chagin KM, Yu C, Sakurada B, Milinovich A, Weng W, Bauman JM, Pantalone KM,

Advertisement

Diabetes, obesity & metabolism 2017 04 13() doi 10.1111/dom.12969
Abstract
AIMS
To assess the potential impact of GLP-1 RA exposure on cardiovascular disease (CVD) and mortality outcomes in patients with type 2 diabetes (T2D), using a large retrospective cohort.

MATERIALS AND METHODS
Patients with T2D between 2005-2014 (N = 105,862) were identified in the electronic health record system at Cleveland Clinic using a validated electronic phenotype. A time-dependent, Cox, multiple regression analysis was used to assess the association between GLP-1 RA exposure and risk of acute myocardial infarction (AMI), stroke/cerebrovascular accident (CVA), and overall mortality, as well as the composite of all three outcomes. The findings were further evaluated by assessing the effect of GLP-1 RA on the same variables in patients with and without prior CVD. The model adjusted for differences in demographic information, hypertension, lab/vitals, past history of outcomes, and T2D medications.

RESULTS
There were significantly lower rates of AMI (hazard ratio [HR] = 0.80, 95% CI=0.65-0.99, P = 0.045), CVA (HR=0.82, 95% CI=0.74-0.91, P < 0.001), overall mortality (HR=0.48, 95% CI=0.41-0.57, P < 0.001), and the composite outcome (HR=0.82, 95% CI=0.74-0.91, P < 0.002) during the consolidated time that patients were exposed to GLP-1 RA compared to corresponding rates during intervals without GLP-1 RA exposure. GLP-1 RA was associated with a significant decrease in CVA, mortality, and the composite outcome in patients with and without established CVD, not significantly affecting AMI in these subgroups. CONCLUSIONS
GLP-1 RA exposure was found to be associated with a reduction in the risk of cardiovascular events observed and overall mortality among patients with T2D with and without established CVD, after adjusting for potential confounders.

Submit a Comment

Your email address will not be published. Required fields are marked *

9 − six =

[ HIDE/SHOW ]